| Hepatitis C virus NS5B RNA-dependent RNA polymerase |
IC50 |
= |
130.0 |
nM |
Inhibition HCV NS5B-mediated RNA synthesis |
CHEMBL1149159 |
| Hepatitis C virus NS5B RNA-dependent RNA polymerase |
EC50 |
|
3500.0 |
nM |
Inhibition HCV RNA replication |
CHEMBL1149159 |
| Nucleic Acid |
EC50 |
= |
3500.0 |
nM |
Inhibition of HCV RNA replication in a subgenomic bicistronic replicon assay in HB-1 cells |
CHEMBL1137984 |
| NON-PROTEIN TARGET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against HB-1 cells in an MTS-based assay |
CHEMBL1137984 |
| Hepatitis C virus |
IC50 |
= |
130.0 |
nM |
Compound was tested for the inhibition of HCV NS5B-mediated RNA synthesis |
CHEMBL1137984 |
| ADMET |
F |
= |
85.0 |
% |
Oral bioavailability in rat |
CHEMBL1137984 |
| Hepatitis C virus |
EC50 |
= |
10800.0 |
nM |
Antiviral activity against HCV replication |
CHEMBL1139016 |
| Huh-7 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against Huh7 cells by MTS assay |
CHEMBL1139016 |
| MT4 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human MT4 cells after 96 hrs by MTT method |
CHEMBL1144007 |
| Bovine viral diarrhea virus |
EC50 |
= |
4000.0 |
nM |
Antiviral activity against BVDV NADL in MDBK cells assessed as protection from virus-induced cytopathogenicity by MTT method |
CHEMBL1144007 |
| Yellow fever virus |
EC50 |
= |
1000.0 |
nM |
Antiviral activity against YFV in BHK cells assessed as protection from virus-induced cytopathogenicity by MTT method |
CHEMBL1144007 |
| Respiratory syncytial virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against RSV A2 in VERO76 cells assessed as reduction of plaque number by MTT method |
CHEMBL1144007 |
| NON-PROTEIN TARGET |
Activity |
|
|
|
Antiviral activity against Human poliovirus 1 Sabin |
CHEMBL1144007 |
| Vesicular stomatitis virus |
Activity |
|
|
|
Antiviral activity against vesicular stomatitis virus |
CHEMBL1144007 |
| Vaccinia virus |
Activity |
|
|
|
Antiviral activity against vaccinia virus |
CHEMBL1144007 |
| Reovirus sp. |
Activity |
|
|
|
Antiviral activity against Reovirus |
CHEMBL1144007 |
| Human immunodeficiency virus 1 |
Activity |
|
|
|
Antiviral activity against HIV1 |
CHEMBL1144007 |
| MT4 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 96 hrs by MTT assay |
CHEMBL1144182 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected MDBK cells assessed as reduction in cell viability after 96 hrs by MTT assay |
CHEMBL1144182 |
| Bovine viral diarrhea virus |
EC50 |
= |
1700.0 |
nM |
Antiviral activity against BVDV infected in MDBK cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay |
CHEMBL1144182 |
| ADMET |
CC50 |
= |
90000.0 |
nM |
Cytotoxicity against mock-infected BHK cells assessed as reduction in cell viability after 96 hrs by MTT assay |
CHEMBL1144182 |
| Yellow fever virus |
EC50 |
= |
1000.0 |
nM |
Antiviral activity against YFV infected in BHK21 cells assessed as protection against virus-induced cytopathogenicity after 4 days by MTT assay |
CHEMBL1144182 |
| Vero |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected african green monkey Vero76 cells assessed as reduction in cell viability after 96 hrs by MTT assay |
CHEMBL1144182 |
| Human coxsackievirus B2 |
EC50 |
= |
20000.0 |
nM |
Antiviral activity against CVB2 infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay |
CHEMBL1144182 |
| Respiratory syncytial virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against RSV infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay |
CHEMBL1144182 |
| Human immunodeficiency virus 1 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Sb1 virus infected in Vero76 cells assessed as reduction in virus plaque formation after 4 days by MTT assay |
CHEMBL1144182 |
| Hepatitis C virus |
EC50 |
= |
3500.0 |
nM |
Antiviral activity against HCV by viral replicon assay |
CHEMBL1153636 |
| Unchecked |
IC50 |
= |
130.0 |
nM |
Inhibition of HCV RNA-dependent RNA polymerase |
CHEMBL1153636 |
| Hepatitis C virus |
EC50 |
= |
10100.0 |
nM |
Antiviral activity against HCV assessed as inhibition of viral replicon replication in human Huh5-2 cells |
CHEMBL1153636 |
| ADMET |
CC50 |
> |
50000.0 |
nM |
Cytotoxicity against human Huh5-2 cells |
CHEMBL1153636 |
| Hepatitis C virus |
EC50 |
= |
2300.0 |
nM |
Antiviral activity against HCV in human Huh7 cells by RNA replicon assay |
CHEMBL1154160 |
| Hepatitis C virus |
EC90 |
= |
7.8 |
uM |
Antiviral activity against HCV in human Huh7 cells by RNA replicon assay |
CHEMBL1154160 |
| Bovine viral diarrhea virus |
EC50 |
= |
1700.0 |
nM |
Antiviral activity against Bovine viral diarrhea virus infected in MDBK cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay |
CHEMBL1154067 |
| Yellow fever virus |
EC50 |
= |
1800.0 |
nM |
Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay |
CHEMBL1154067 |
| Mammalian orthoreovirus 1 |
EC50 |
= |
2400.0 |
nM |
Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay |
CHEMBL1154067 |
| Human coxsackievirus B2 |
EC50 |
= |
20000.0 |
nM |
Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay |
CHEMBL1154067 |
| ADMET |
CC50 |
= |
90000.0 |
nM |
Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay |
CHEMBL1154067 |
| MT4 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human MT4 cells after 96 hrs by MTT assay |
CHEMBL1154067 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDBK cells after 48 to 96 hrs by MTT assay |
CHEMBL1154067 |
| Vero |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining |
CHEMBL1154067 |
| Respiratory syncytial virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay |
CHEMBL1154067 |
| Human herpesvirus 1 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay |
CHEMBL1154067 |
| NON-PROTEIN TARGET |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Human poliovirus 1 strain Sabin after 2 days by plaque reduction assay |
CHEMBL1154067 |
| Human immunodeficiency virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against HIV in human PBM cells by RNA replicon assay |
CHEMBL1154160 |
| PBMC |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human PBMC cells |
CHEMBL1154160 |
| CCRF-CEM |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human CEM cells |
CHEMBL1154160 |
| Vero |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against african green monkey Vero cells |
CHEMBL1154160 |
| Human immunodeficiency virus |
EC90 |
> |
100.0 |
uM |
Antiviral activity against HIV in human PBM cells by RNA replicon assay |
CHEMBL1154160 |
| Human poliovirus 1 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay |
CHEMBL1156237 |
| Human coxsackievirus B2 |
EC50 |
= |
20000.0 |
nM |
Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay |
CHEMBL1156237 |
| Yellow fever virus |
EC50 |
= |
1800.0 |
nM |
Antiviral activity against Yellow fever virus 17D infected in BHK cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method |
CHEMBL1156237 |
| Bovine viral diarrhea virus |
EC50 |
= |
1700.0 |
nM |
Antiviral activity against Bovine viral diarrhea virus NADL infected in MDBK cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method |
CHEMBL1156237 |
| Vero |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against african green monkey Vero cells |
CHEMBL1156237 |
| ADMET |
CC50 |
= |
90000.0 |
nM |
Cytotoxicity against BHK cells after 48 to 96 hrs by MTT assay |
CHEMBL1156237 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDBK cells after 48 to 96 hrs by MTT assay |
CHEMBL1156237 |
| MT4 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human MT4 cells after 96 hrs by MTT assay |
CHEMBL1156237 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay |
CHEMBL1156237 |
| Respiratory syncytial virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay |
CHEMBL1156237 |
| Human herpesvirus 1 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay |
CHEMBL1156237 |
| Mammalian orthoreovirus 1 |
EC50 |
= |
2400.0 |
nM |
Antiviral activity against Reovirus 1 3651 infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method |
CHEMBL1156237 |
| Liver |
AUC |
= |
36868.0 |
hr.ng/g |
AUC (0 to 24 hrs) in ICR mouse liver at 50 mg/kg, po by LC-MS/MS analysis |
CHEMBL1177718 |
| Mus musculus |
F |
= |
85.0 |
% |
Oral bioavailability in ICR mouse at 50 mg/kg |
CHEMBL1177718 |
| Cynomolgus monkey |
F |
= |
10.0 |
% |
Oral bioavailability in cynomolgus monkey at 50 mg/kg |
CHEMBL1177718 |
| Liver |
AUC |
= |
16510.0 |
hr.ng/g |
AUC (0 to 6 hrs) in ICR mouse liver at 50 mg/kg, po by LC-MS/MS analysis |
CHEMBL1177718 |
| Liver |
Clast |
= |
390.0 |
ng/ml |
Clast in ICR mouse liver at 50 mg/kg, po by LC-MS/MS analysis |
CHEMBL1177718 |
| Liver |
Cmax |
= |
3470.0 |
ng/g |
Cmax in ICR mouse liver at 50 mg/kg, po by LC-MS/MS analysis |
CHEMBL1177718 |
| Hepatitis C virus |
EC50 |
= |
3500.0 |
nM |
Antiviral activity against HCV1b infected in human HuH7 cells assessed as inhibition of viral replication after 48 hrs by luciferase reporter gene assay |
CHEMBL1177718 |
| Huh-7 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human HuH7 cells after 72 hrs by celltiter-glo assay |
CHEMBL1177718 |
| Plasma |
Cmax |
= |
17502.61 |
nM |
Cmax in ICR mouse plasma at 50 mg/kg, po by LC-MS/MS analysis |
CHEMBL1177718 |
| Plasma |
Clast |
= |
22.0 |
ng/ml |
Clast in ICR mouse plasma at 50 mg/kg, po by LC-MS/MS analysis |
CHEMBL1177718 |
| Plasma |
T1/2 |
= |
5.4 |
hr |
Half life in ICR mouse plasma at 50 mg/kg, po by LC-MS/MS analysis |
CHEMBL1177718 |
| Plasma |
AUC |
= |
20390.0 |
ng.hr.mL-1 |
AUC (0 to t) in ICR mouse plasma at 50 mg/kg, po by LC-MS/MS analysis |
CHEMBL1177718 |
| Plasma |
AUC |
= |
20567.0 |
ng.hr.mL-1 |
AUC (0 to infinity) in ICR mouse plasma at 50 mg/kg, po by LC-MS/MS analysis |
CHEMBL1177718 |
| Plasma |
AUC |
= |
411.0 |
ng.hr.mL-1 |
Dose normalized AUC in ICR mouse plasma at 50 mg/kg, po by LC-MS/MS analysis |
CHEMBL1177718 |
| Liver |
AUC |
= |
737.0 |
hr.ng/g |
Dose normalized AUC in ICR mouse liver at 50 mg/kg, po by LC-MS/MS analysis |
CHEMBL1177718 |
| Bovine viral diarrhea virus |
EC50 |
= |
1700.0 |
nM |
Antiviral activity against BVDV infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity by MTT assay |
CHEMBL1212868 |
| ADMET |
CC50 |
> |
10000.0 |
nM |
Cytotoxicity against MDBK cells after 48 to 96 hrs by MTT assay |
CHEMBL1938334 |
| NON-PROTEIN TARGET |
EC50 |
= |
1100.0 |
nM |
Antiviral activity against Bovine viral diarrhea virus 1-NADL infected in MDBK cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL1938334 |
| BHK-21 |
CC50 |
> |
10000.0 |
nM |
Cytotoxicity against BHK21 cells after 48 to 96 hrs by MTT assay |
CHEMBL1938334 |
| NON-PROTEIN TARGET |
EC50 |
= |
1900.0 |
nM |
Antiviral activity against Yellow fever virus 17D Stamaril Pasteur J07B01 infected in hamster BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL1938334 |
| Unchecked |
EC50 |
= |
3500.0 |
nM |
Inhibition of Hepatitis C virus NS5B RNA-dependent RNA polymerase |
CHEMBL2021855 |
| Rattus norvegicus |
F |
= |
85.0 |
% |
Oral bioavailability in rat |
CHEMBL2021855 |
| Hepatitis C virus |
EC50 |
= |
3250.0 |
nM |
Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as cytoprotection after 24 hrs |
CHEMBL2029282 |
| Huh-7 |
CC50 |
> |
89000.0 |
nM |
Cytotoxicity against human HuH7 cells after 24 hrs by MTS assay |
CHEMBL2029282 |
| Hepatitis C virus |
IC50 |
= |
250.0 |
nM |
Inhibition of HCV genotype 1b NS5B after 90 mins |
CHEMBL2029282 |
| ADMET |
CC50 |
> |
10000.0 |
nM |
Cytotoxicity against MDBK cells after 48 to 96 hrs by MTT assay |
CHEMBL2034874 |
| NON-PROTEIN TARGET |
EC50 |
= |
1100.0 |
nM |
Antiviral activity against BVDV1 NADL ATCC VR-534 infected in MDBK cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL2034874 |
| BHK-21 |
CC50 |
> |
10000.0 |
nM |
Cytotoxicity against BHK21 cells by MTT assay |
CHEMBL2034874 |
| NON-PROTEIN TARGET |
EC50 |
= |
1900.0 |
nM |
Antiviral activity against Yellow fever virus 17D infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL2034874 |
| Hepatitis C virus |
EC50 |
= |
2200.0 |
nM |
Antiviral activity against Hepatitis C virus subtype 1b Con1 infected in human Huh7 cells assessed as inhibition of HCV replicon-encoded Renilla luciferase reporter activity after 72 hrs by HCV replicon assay |
CHEMBL2150978 |
| Hepatitis C virus |
EC90 |
= |
8.3 |
uM |
Antiviral activity against Hepatitis C virus subtype 1b Con1 infected in human Huh7 cells assessed as inhibition of HCV replicon-encoded Renilla luciferase reporter activity after 72 hrs by HCV replicon assay |
CHEMBL2150978 |
| Huh-7 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human HuH7 cells after 3 days |
CHEMBL2150978 |
| Yellow fever virus |
EC50 |
= |
2500.0 |
nM |
Antiviral activity against Yellow fever virus infected Syrian hamster BHK-21 cells assessed as protection against virus-induced cytopathogenicity treated 1 hr after viral infection measured after 3-4 days by MTT method |
CHEMBL3046811 |
| Bovine viral diarrhea virus |
EC50 |
= |
1800.0 |
nM |
Antiviral activity against Bovine viral diarrhea virus 1 infected bovine MDBK cells assessed as protection against virus-induced cytopathogenicity treated 1 hr after viral infection measured after 3-4 days by MTT method |
CHEMBL3046811 |
| Hepatitis C virus |
EC50 |
= |
2000.0 |
nM |
Antiviral activity against Hepatitis C virus assessed as inhibition of subgenomic replicon RNA replication |
CHEMBL3286396 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected bovine MDBK cells assessed as reduction in proliferation after 72 hrs by MTT method |
CHEMBL3352401 |
| NON-PROTEIN TARGET |
EC50 |
= |
1100.0 |
nM |
Antiviral activity against Bovine viral diarrhea virus 1-NADL ATCC VR-534 infected in MDBK cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method |
CHEMBL3352401 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected hamster BHK21 cells assessed as reduction in proliferation after 72 hrs by MTT method |
CHEMBL3352401 |
| NON-PROTEIN TARGET |
EC50 |
= |
1900.0 |
nM |
Antiviral activity against Yellow fever virus 17D Stamaril Pasteur J07B01 infected in BHK21 cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method |
CHEMBL3352401 |
| MT4 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay |
CHEMBL3351523 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected MDBK cells after 48 to 96 hrs by MTT assay |
CHEMBL3351523 |
| Bovine viral diarrhea virus |
EC50 |
= |
1700.0 |
nM |
Antiviral activity against Bovine viral diarrhea virus infected in MDBK cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3351523 |
| NON-PROTEIN TARGET |
CC50 |
= |
90000.0 |
nM |
Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay |
CHEMBL3351523 |
| Yellow fever virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3351523 |
| Reovirus sp. |
EC50 |
= |
2400.0 |
nM |
Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3351523 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay |
CHEMBL3351523 |
| Human coxsackievirus B5 |
EC50 |
= |
20000.0 |
nM |
Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay |
CHEMBL3351523 |
| Human poliovirus 1 strain Sabin |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay |
CHEMBL3351523 |
| Respiratory syncytial virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay |
CHEMBL3351523 |
| Vesicular stomatitis virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay |
CHEMBL3351523 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay |
CHEMBL3351523 |
| Human herpesvirus 1 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay |
CHEMBL3351523 |
| Unchecked |
Ratio CC50/EC50 |
> |
5.0 |
|
Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for Coxsackievirus B5 |
CHEMBL3351523 |
| ADMET |
CC50 |
> |
10000.0 |
nM |
Cytotoxicity against bovine MDBK cells assessed as cell viability after 48 to 96 hrs by MTT assay |
CHEMBL3616436 |
| NON-PROTEIN TARGET |
EC50 |
= |
1100.0 |
nM |
Antiviral activity against Bovine viral diarrhea virus 1-NADL ATCC VR-534 infected in MDBK cells assessed as protection against virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3616436 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against BHK cells assessed as cell viability after 48 to 96 hrs by MTT assay |
CHEMBL3616436 |
| NON-PROTEIN TARGET |
EC50 |
= |
1900.0 |
nM |
Antiviral activity against Yellow fever virus 17D infected in BHK cells assessed as protection against virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3616436 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDBK cells assessed as reduction in cell viability after 72 hrs by MTT assay |
CHEMBL3734708 |
| ADMET |
CC50 |
= |
1100.0 |
nM |
Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 72 hrs by MTT assay |
CHEMBL3734708 |
| Yellow fever virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against YFV 17-D vaccine (Stamaril Pasteur J07B01) infected in BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 or 4 days by MTT assay |
CHEMBL3734708 |
| NON-PROTEIN TARGET |
EC50 |
= |
1900.0 |
nM |
Antiviral activity against Reovirus 1 ATCC VR- 214 infected in BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 or 4 days by MTT assay |
CHEMBL3734708 |
| MT4 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay |
CHEMBL3734667 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDBK cells assessed as cell viability after 48 to 96 hrs by MTT assay |
CHEMBL3734667 |
| ADMET |
CC50 |
> |
60000.0 |
nM |
Cytotoxicity against BHK cells assessed as cell viability after 48 to 96 hrs by MTT assay |
CHEMBL3734667 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method |
CHEMBL3734667 |
| Bovine viral diarrhea virus |
EC50 |
= |
1700.0 |
nM |
Antiviral activity against BVDV infected in MDBK cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3734667 |
| Yellow fever virus |
EC50 |
= |
1500.0 |
nM |
Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3734667 |
| NON-PROTEIN TARGET |
EC50 |
= |
2400.0 |
nM |
Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3734667 |
| Human coxsackievirus B5 |
EC50 |
= |
20000.0 |
nM |
Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay |
CHEMBL3734667 |
| Human respiratory syncytial virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay |
CHEMBL3734667 |
| Human poliovirus 1 strain Sabin |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay |
CHEMBL3734667 |
| Unchecked |
Ratio CC50/EC50 |
> |
58.8 |
|
Selectivity index, ratio of CC50 for MDBK cells to EC50 for BVDV |
CHEMBL3734667 |
| Unchecked |
Ratio CC50/EC50 |
> |
66.7 |
|
Selectivity index, ratio of CC50 for BHK-21 cells to EC50 for YFV |
CHEMBL3734667 |
| Unchecked |
Ratio CC50/EC50 |
> |
5.0 |
|
Selectivity index, ratio of CC50 for african green monkey Vero76 cells to EC50 for human CVB5 |
CHEMBL3734667 |
| Human immunodeficiency virus 1 |
EC50 |
|
|
|
Antiviral activity against HIV-1 infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay |
CHEMBL3734667 |
| Dengue virus 2 |
EC50 |
= |
1200.0 |
nM |
Antiviral activity against DENV-2 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3734667 |
| West Nile virus |
EC50 |
= |
700.0 |
nM |
Antiviral activity against WNV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3734667 |
| Human herpesvirus 1 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against HSV1 |
CHEMBL3734667 |
| Vesicular stomatitis virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against VSV |
CHEMBL3734667 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus |
CHEMBL3734667 |
| NON-PROTEIN TARGET |
EC50 |
= |
1100.0 |
nM |
Antiviral activity against BVDV NADL infected in MDBK cells assessed as inhibition of virus induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3808296 |
| ADMET |
CC50 |
> |
10000.0 |
nM |
Cytotoxicity against mock-infected MDBK cells assessed as reduction in cell viability after 72 hrs by MTT assay |
CHEMBL3808296 |
| Unchecked |
Ratio CC50/EC50 |
> |
9.1 |
|
Selectivity index, ratio of CC50 for MDBK cells to EC50 for mock-infected BVDV NADL infected in MDBK cells |
CHEMBL3808296 |
| ADMET |
CC50 |
> |
10000.0 |
nM |
Cytotoxicity against mock-infected BHK21 cells assessed as reduction in cell viability after 72 hrs by MTT assay |
CHEMBL3808296 |
| NON-PROTEIN TARGET |
EC50 |
= |
1900.0 |
nM |
Antiviral activity against Yellow fever virus 17D infected in BHK21 cells assessed as inhibition of virus induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3808296 |
| NON-PROTEIN TARGET |
EC50 |
|
|
|
Antiviral activity against Reovirus type-1 3651 infected in BHK21 cells assessed as inhibition of virus induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3808296 |
| ADMET |
CC50 |
|
|
|
Cytotoxicity against mock-infected african green monkey Vero 76 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay |
CHEMBL3808296 |
| Human coxsackievirus B2 |
EC50 |
|
|
|
Antiviral activity against CVB-2 infected in Vero 76 cells after 3 days by crystal violet staining based plaque reduction assay |
CHEMBL3808296 |
| Human poliovirus 1 strain Sabin |
EC50 |
|
|
|
Antiviral activity against Human poliovirus 1 strain Sabin infected in Vero 76 cells after 2 days by crystal violet staining based plaque reduction assay |
CHEMBL3808296 |
| Respiratory syncytial virus |
EC50 |
|
|
|
Antiviral activity against Respiratory syncytial virus A2 infected in Vero 76 cells after 5 days by crystal violet staining based plaque reduction assay |
CHEMBL3808296 |
| Vesicular stomatitis virus |
EC50 |
|
|
|
Antiviral activity against Vesicular stomatitis virus Indiana infected in Vero 76 cells after 2 days by crystal violet staining based plaque reduction assay |
CHEMBL3808296 |
| Vaccinia virus |
EC50 |
|
|
|
Antiviral activity against Vaccinia virus Elstree infected in Vero 76 cells after 3 days by crystal violet staining based plaque reduction assay |
CHEMBL3808296 |
| Dengue virus 2 |
Inhibition |
|
|
% |
Antiviral activity against Dengue virus 2 prototype 16681 infected in African green monkey Vero cells assessed as inhibition of viral RNA replication at 100 uM after 72 hrs in presence of 100 uM of HINT1 inhibitor TpGc by qPCR method |
CHEMBL4130454 |
| Vero |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 72 hrs by neutral red dye uptake assay |
CHEMBL4130454 |
| Dengue virus 2 |
IC50 |
= |
8140.0 |
nM |
Antiviral activity against Dengue virus 2 prototype 16681 infected in BHK cells assessed as inhibition of virus induced cytopathic effect by plaque assay |
CHEMBL4130454 |
| Dengue virus 2 |
Inhibition |
|
|
% |
Antiviral activity against Dengue virus 2 prototype 16681 infected in African green monkey Vero cells assessed as inhibition of viral RNA replication at 100 uM after 72 hrs by qPCR method |
CHEMBL4130454 |
| Dengue virus 2 |
EC50 |
= |
13600.0 |
nM |
Antiviral activity against Dengue virus 2 New Guinea assessed as inhibition of virus induced cytopathic effect by neutral red dye uptake assay |
CHEMBL4130454 |
| Yellow fever virus |
EC50 |
= |
48000.0 |
nM |
Antiviral activity against Yellow fever virus 17D vaccine (Stamaril Pasteur J07B01) infected in golden hamster BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 to 4 days by MTT assay |
CHEMBL4130485 |
| Dengue virus 2 |
EC50 |
= |
1700.0 |
nM |
Antiviral activity against Dengue virus type 2 clinical isolate infected in golden hamster BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 to 4 days by MTT assay |
CHEMBL4130485 |
| West Nile virus |
EC50 |
= |
800.0 |
nM |
Antiviral activity against West Nile virus clinical isolate infected in golden hamster BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 to 4 days by MTT assay |
CHEMBL4130485 |
| Unchecked |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDBK cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay |
CHEMBL4145483 |
| Bovine viral diarrhea virus |
EC50 |
= |
1100.0 |
nM |
Antiviral activity against BVDV NADL ATCC VR-534 infected in MDBK cells assessed as protection against virus-induced cytopathic effect after 3 to 4 days by MTT assay |
CHEMBL4145483 |
| BHK-21 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against golden hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay |
CHEMBL4145483 |
| Mammalian orthoreovirus 1 |
EC50 |
= |
1900.0 |
nM |
Antiviral activity against Reovirus 1 3651 ATCC VR-214 infected in golden hamster BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 to 4 days by MTT assay |
CHEMBL4145483 |
| Yellow fever virus |
EC50 |
= |
1900.0 |
nM |
Antiviral activity against Yellow fever virus 17D infected in golden hamster BHK21 cells assessed as protection against virus-induced cytopathic effect after 3 to 4 days by MTT assay |
CHEMBL4145483 |
| SARS-CoV-2 |
Inhibition |
= |
-4.33 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging |
CHEMBL4303101 |
| West Nile virus |
EC50 |
= |
30000.0 |
nM |
Antiviral activity against West Nile virus |
CHEMBL4480403 |
| Replicase polyprotein 1ab |
Inhibition |
= |
15.15 |
% |
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate |
CHEMBL4495564 |
| SARS-CoV-2 |
Inhibition |
= |
-0.03 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| SARS-CoV-2 |
Inhibition |
= |
-0.03 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
